'Molecular diagnostics' diaporamas de présentation

Emerging Developments and Your Future in Pathology

Emerging Developments and Your Future in Pathology. Jared N. Schwartz, MD, PhD, FCAP President, College of American Pathologists Presbyterian Health Charlotte, NC John Winbern Turner, MD, FCAP Johnston-Willis Hospital Richmond, VA. Emerging Developments and Your Future in Pathology.

1.13k views • 64 slides

Evaluation of Albuminuria

Evaluation of Albuminuria. Adapted from Lamb EJ, Price CP. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, p. 669-708, 2012.

673 views • 56 slides

BIOMARKERS

BIOMARKERS. Diagnostics and Prognostics. OMICS. Molecular Diagnostics: Promises and Possibilities, p. 12 and 26.

559 views • 28 slides

Advantages in Developing a MDx Lab

Advantages in Developing a MDx Lab. RCM Enterprise Services Mark Droste. Brief History. For decades Genetic testing was associated with Universities, and Reference Labs focused on rapid DNA sequencing.

442 views • 26 slides

Sophomore and Transfers Pre-health Advising Workshop

Dr. Diane Davis Ms. Marylane McGlinchey. Sophomore and Transfers Pre-health Advising Workshop. What is the Health Professions Advising Program? (HPAP). Director, Dr. Diane Davis Advisors and support structure. Maintain Website Coordinate with academic departments Email for questions

340 views • 21 slides

Partnerships & Alliances Molecular Diagnostics

Partnerships & Alliances Molecular Diagnostics. Prof. K. K. Jain MD, FRACS, FFPM CEO, Jain PharmaBiotech Blaesiring 7, 4057 Basel, Switzerland Colloquim B: Strategies for Business Success IBC Molecular Diagnostics Meets Therapeutics Boston, 4 June 2002. Molecular Diagnostic Technologies.

1.08k views • 19 slides

Cancer: The Survivorship and Inequality Challenges

Cancer: The Survivorship and Inequality Challenges. Professor Sir Mike Richards July 2010 Leeds. Overview. The Coalition Government Cancer: The Key Challenges Focus on survivorship and inequalities. Coalition Government: Priorities.

410 views • 18 slides

Introduction

Risk of misdiagnosis due to allele dropout in molecular diagnostics: analysis of 30769 genotypes.

237 views • 18 slides

Coordination Office: Andrzej C. Składanowski Ewa Kiszka

Centre of Excellence in Bio-safety and Molecular Biomedicine - „BioMoBiL” Sixth Meeting of the Working Package WP7 „Final Report and What Did We Achieve ?” Gdańsk, 29 June 2006 Department of Biology and Pharmaceutical Botany, Faculty of Pharmacy, MUG. Coordination Office:

283 views • 17 slides

e-Science: A Philips Research Perspective

e-Science: A Philips Research Perspective. Emile Aarts. Acknowledgement: Serge Vrijaldenhoven Arie Kaizer. Developments in digitization. 1548. 1584. Did You know by Scott McLeod . The number of text messages sent and received every day exceeds the population of the planet.

539 views • 16 slides

e-Science: A Philips Research Perspective

e-Science: A Philips Research Perspective. Emile Aarts. Acknowledgement: Serge Vrijaldenhoven Arie Kaizer. Developments in digitization. 1548. 1584. Did You know by Scott McLeod . The number of text messages sent and received every day exceeds the population of the planet.

285 views • 16 slides

Genetic Discovery and the Need for Compulsory Licensing

Genetic Discovery and the Need for Compulsory Licensing. Jon F. Merz Department of Medical Ethics and Center for Bioethics University of Pennsylvania School of Medicine. Acknowledgements. NHGRI/ELSI for funding

268 views • 16 slides

Mechanism of Antibody Based Diagnostic Tests

PHM142 Fall 2012 Instructor: Dr. Jeffrey Henderson. Mechanism of Antibody Based Diagnostic Tests. Presented By: Colette Papagiannis, Boya(Connie) Xiong and Tianna Costa. Overview. What is an antibody? Antibody Techniques ELISA Indirect Sandwich Competitive Methods of Detection

421 views • 16 slides

Molecular diagnostics in pediatric glial tumors

Molecular diagnostics in pediatric glial tumors. Joon-Hyung Kim, MSIV Weill Cornell Medical College. Key molecular alterations in pediatric glial tumors. Anaplastic oligodendroglioma in adults (n=64). Progression Free Survival. Overall Survival. Snuderl et al. Clin Cancer Res 2009.

293 views • 16 slides

About

348 views • 15 slides

How Do I Know if My Invention Has Commercial Potential ? Beth Drees Team Lead, Health Sciences

How Do I Know if My Invention Has Commercial Potential ? Beth Drees Team Lead, Health Sciences. Why Commercialize?. Commercialization: Translates research findings into practical applications. Allows public benefit from tax-supported research.

226 views • 15 slides

Momenta Pharmaceuticals, Inc.

408 views • 14 slides

Proteomics - Technologies, Markets and Companies

Bharat Book Presents"Proteomics - Technologies, Markets and Companies"describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century.

171 views • 7 slides

JSB Market Research: In Vitro Diagnostic (IVD) Market Techn

In the report, the market has been segmented on the basis of technology, product type, application, and end-users. On the basis of technology, the molecular diagnostics market is expected to grow at the highest CAGR from 2012 to 2017.

233 views • 7 slides

Molecular Diagnostics Market : Trends , Opportunities and M

Molecular Diagnostics Market - Technologies [PCR, DNA Sequencing, Microarray, Transcription Mediated Amplification, Hybridization], Applications Virology/Infectious Diseases, Cancer/ Oncology, Genetic Testing, Blood Screening, Microbiology] Global Opportunities, Competitor Analysis

320 views • 6 slides